Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
Clinical trial NCT01323517 · COMPLETED
Trial details
- NCT number
- NCT01323517
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-02-01
- Primary completion
- 2017-08-14
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.